Kramer J, Bar-Or A, Turner T, Wiendl H
Nat Rev Neurol. 2023; 19(5):289-304.
PMID: 37055617
PMC: 10100639.
DOI: 10.1038/s41582-023-00800-7.
Feng Y, Wang Z, Yang N, Liu S, Yan J, Song J
Front Cell Dev Biol. 2021; 9:724172.
PMID: 34414195
PMC: 8369412.
DOI: 10.3389/fcell.2021.724172.
Girard J, Reneau J, Devata S, Wilcox R, Kaminski M, Mercer J
Onco Targets Ther. 2019; 12:8003-8014.
PMID: 31686856
PMC: 6777435.
DOI: 10.2147/OTT.S155778.
Sid H, Schusser B
Front Genet. 2018; 9:456.
PMID: 30356667
PMC: 6189320.
DOI: 10.3389/fgene.2018.00456.
Yim J, Yun J, Kim J, Lee I, Nam S, Kim C
J Radiat Res. 2017; 58(3):329-340.
PMID: 28122968
PMC: 5440887.
DOI: 10.1093/jrr/rrw126.
Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R, Kumar R, Choi L, Lee K
PLoS One. 2016; 11(1):e0147190.
PMID: 26784025
PMC: 4718466.
DOI: 10.1371/journal.pone.0147190.
A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATOR.
Uckun F, Ma H, Ozer Z, Goodman P, Zhang J, Qazi S
EBioMedicine. 2014; 1(1):16-28.
PMID: 25506060
PMC: 4259291.
DOI: 10.1016/j.ebiom.2014.10.019.
Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.
Ma H, Qazi S, Ozer Z, Zhang J, Ishkhanian R, Uckun F
PLoS One. 2013; 8(8):e71302.
PMID: 23977012
PMC: 3747153.
DOI: 10.1371/journal.pone.0071302.
Novel Bruton's tyrosine kinase inhibitors currently in development.
DCruz O, Uckun F
Onco Targets Ther. 2013; 6:161-76.
PMID: 23493945
PMC: 3594038.
DOI: 10.2147/OTT.S33732.
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.
Balakrishnan K, Gandhi V
Expert Opin Investig Drugs. 2012; 21(4):409-23.
PMID: 22409342
PMC: 4142764.
DOI: 10.1517/13543784.2012.668526.
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.
Uckun F, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z
Proc Natl Acad Sci U S A. 2010; 107(7):2902-7.
PMID: 20133729
PMC: 2840303.
DOI: 10.1073/pnas.0909086107.
Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation.
Zemans R, Arndt P
Cell Immunol. 2009; 258(1):90-7.
PMID: 19393603
PMC: 2697619.
DOI: 10.1016/j.cellimm.2009.03.017.
BLNK binds active H-Ras to promote B cell receptor-mediated capping and ERK activation.
Imamura Y, Oda A, Katahira T, Bundo K, Pike K, Ratcliffe M
J Biol Chem. 2009; 284(15):9804-13.
PMID: 19218240
PMC: 2665102.
DOI: 10.1074/jbc.M809051200.
Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk.
Spatuzza C, Schiavone M, Di Salle E, Janda E, Sardiello M, Fiume G
Nucleic Acids Res. 2008; 36(13):4402-16.
PMID: 18596081
PMC: 2490745.
DOI: 10.1093/nar/gkn413.
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.
Feldhahn N, Rio P, Soh B, Liedtke S, Sprangers M, Klein F
Proc Natl Acad Sci U S A. 2005; 102(37):13266-71.
PMID: 16141323
PMC: 1201599.
DOI: 10.1073/pnas.0505196102.
Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors.
Schmidt U, van den Akker E, Parren-van Amelsvoort M, Litos G, de Bruijn M, Gutierrez L
J Exp Med. 2004; 199(6):785-95.
PMID: 15007095
PMC: 2212722.
DOI: 10.1084/jem.20031109.
A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria.
Wiltshire C, Matsushita M, Tsukada S, Gillespie D, May G
Biochem J. 2002; 367(Pt 3):577-85.
PMID: 12167088
PMC: 1222945.
DOI: 10.1042/BJ20020553.
Biochemical identification of a neutral sphingomyelinase 1 (NSM1)-like enzyme as the major NSM activity in the DT40 B-cell line: absence of a role in the apoptotic response to endoplasmic reticulum stress.
Fensome A, Josephs M, Katan M, Rodrigues-Lima F
Biochem J. 2002; 365(Pt 1):69-77.
PMID: 12071841
PMC: 1222658.
DOI: 10.1042/BJ20020120.
A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.
Tomlinson M, Woods D, McMahon M, Wahl M, Witte O, Kurosaki T
BMC Immunol. 2001; 2:4.
PMID: 11410123
PMC: 32313.
DOI: 10.1186/1471-2172-2-4.
Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with antileukemic activity.
Chen C, Tai H, Zhu D, Uckun F
Pharm Res. 1999; 16(7):1003-9.
PMID: 10450923
DOI: 10.1023/a:1018923430094.